<DOC>
	<DOCNO>NCT01387321</DOCNO>
	<brief_summary>In study , BYL719 administer adult patient advance solid tumor whose disease progress despite standard therapy standard therapy exist . The trial investigate safety tolerability determine MTD BYL719 Japanese patient .</brief_summary>
	<brief_title>A Study BYL719 Adult Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<criteria>Patients histologicallyconfirmed , advance unresectable solid tumor Availability representative formalin fix paraffin embed tumor tissue sample At least one measurable nonmeasurable lesion Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Good organ ( hepatic , kidney , BM ) function screening/baseline visit Brain metastasis unless treat free signs/symptoms attributable brain metastasis absence corticosteroid therapy antiepileptic therapy . Prior treatment PI3K inhibitor Patient peripheral neuropathy NCICTC Grade ≥ 2 Patient diarrhea NCICTC Grade ≥ 2 Patient acute chronic pancreatitis Impaired cardiac function clinically significant cardiac disease incl unstable angina pectoris ≤ 3 month prior start study drug Acute Myocardial Infarction ( AMI ) ≤ 3 month prior start study drug Patients clinically manifest diabetes mellitus , history gestational diabetes mellitus document steroidinduced diabetes mellitus Women pregnant breast feeding adult reproductive potential employ effective method birth control Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Pi3K</keyword>
	<keyword>Advanced solid tumor</keyword>
</DOC>